ArticlePloS one2025
Ensemble deep learning for Alzheimer's disease diagnosis using MRI: Integrating features from VGG16, MobileNet, and InceptionResNetV2 models.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Advances in AI-based diagnosis of Alzheimer's disease using MRI: a comprehensive survey.Frontiers in medicine · 2026Review
- FuzzyFed-CNN: secure and explainable multimodal federated learning for early Alzheimer's diagnosis.Frontiers in artificial intelligence · 2026Article
- Review of deep learning models for Alzheimer's disease detection: MRI-centric approaches and multimodal extensions.Frontiers in artificial intelligence · 2026Review
- Lightweight Deep Learning Models with Explainable AI for Early Alzheimer's Detection from Standard MRI Scans.Diagnostics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by the accumulation of amyloid plaques and neurofibrillary tangles in the brain, leading to distinctive patterns of neuronal dysfunction and the cognitive decline emblematic of dementia. Currently, over 5 million individuals aged 65 and above are living with AD in the United States, a number projected to rise by 2050. Traditional diagnostic methods are fraught with challenges, including low accuracy and a significant propensity for misdiagnosis. In response to these diagnostic challenges, our study develops and evaluates an innovative deep learning (DL) ensemble model that integrates features from three pre-trained models-VGG16, MobileNet, and InceptionResNetV2-for the precise identification of AD markers from MRI scans. This approach aims to overcome the limitations of individual models in handling varying image shapes and textures, thereby improving diagnostic accuracy. The ultimate goal is to support primary radiologists by streamlining the diagnostic process, facilitating early detection, and enabling timely treatment of AD. Upon rigorous evaluation, our ensemble model demonstrated superior performance over contemporary classifiers, achieving a notable accuracy of 97.93%, along with a specificity of 98.04%, sensitivity of 95.89%, precision of 95.94%, and an F1-score of 87.50%. These results not only underscore the efficacy of the ensemble approach but also highlight the potential for DL to revolutionize AD diagnosis, offering a promising pathway to more accurate, early detection and intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.